Nkarta, Inc. Common Stock NKTX
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $11.25 (+800.0% upside)
Key Stats
- Today's Range
- $1.15 – $1.28
- 50-Day Range
- $1.10 – $3.20
- 52-Week Range
- $1.10 – $3.72
- Volume
- 1.04 million shs
- Average Volume
- 1.46 million shs
- Market Cap
- $86.67 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.09%
- Days to Cover
- 1.00
About Nkarta, Inc. Common Stock
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Related Stocks
Compare head-to-head: NKTX vs LLY·NKTX vs JNJ·NKTX vs ABBV·NKTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
